CD4+T cells in antitumor immunity: utility of an Ii-Key HER2/neu hybrid peptide vaccine (AE37)
Author:
Publisher
Informa Healthcare
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
http://www.tandfonline.com/doi/pdf/10.1517/14712590802614538
Reference49 articles.
1. Tumor antigens recognized by T cells
2. The E75 HER2/neu peptide vaccine
3. Cancer vaccines based on the identification of genes encoding cancer regression antigens
4. New tumor antigens recognized by T cells
5. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Peptide antitumor vaccines targeting HER2/neu;Russian Journal of Biotherapy;2022-12-10
2. Potential association factors for developing effective peptide-based cancer vaccines;Frontiers in Immunology;2022-07-27
3. AE36 HER2/neu-derived peptide linked to positively charged liposomes with CpG-ODN as an effective therapeutic and prophylactic vaccine for breast cancer;Journal of Drug Delivery Science and Technology;2022-01
4. Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer;Cancers;2021-01-06
5. Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19;Journal of Drug Targeting;2020-07-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3